Provention Bio (PRVB) Confirms FDA Advisory Committee Votes in Favor of Benefits of Teplizumab Outweighing Risks in Support of Approval to Delay Clinical Type 1 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. BLZE
8. NKE
9. MU
10. ACN

Go back to Provention Bio (PRVB) Confirms FDA Advisory Committee Votes in Favor of Benefits of Teplizumab Outweighing Risks in Support of Approval to Delay Clinical Type 1 Diabetes

Provention Bio Inc. (PRVB) PT Lowered to $22.50 at Chardan Capital Markets Following FDA AdComm Vote

May 28, 2021 9:29 AM EDT

Chardan Capital Markets analyst Gbola Amusa lowered the price target on Provention Bio Inc. (NASDAQ: PRVB) to $22.50 (from $35.00) while maintaining a Buy rating following the FDA Advisory Committee vote.

The analyst commented, "Provention Bio (Buy): Yesterday, the FDA Advisory Committee (EMDAC)... More

Provention Bio Inc. (PRVB) to Resume Trading at 7:10 a.m.

May 28, 2021 7:08 AM EDT

Provention Bio Inc. (NASDAQ: PRVB) to Resume Trading at 7:10 a.m.

... More